Precision Cancer Modeling
Precision Cancer Modeling (PCM) has been established primarily to enable well-designed, scientifically sound preclinical studies for drug development. We are experienced in utilizing standard as well as custom designed in vivo cancer models best suited for pharmacological evaluation of experimental therapies.
At the center, we are constantly characterizing and validating cancer models which are kept in a ready state for application in investigation of experimental therapeutic approaches targeting cancer and related pathologies. These cancer models can be utilized for investigation of anti cancer drugs in monotherapy or combination therapy settings.
PCM can organize and carry-out a full suite of preclinical evaluation of the drug candidates of interest which typically involves: Toxicology (Tox), Pharmacokinetics (PK), and Pharmacodynamics (PD) studies. The experiments can be highly customized to suit the candidate drug.
The PCM will be your collaborator in generating high quality data for academic publications as well data packages for regulatory applications and commercial development. PCM runs small animal imaging facilities at the medical school and the West Campus consisting of clusters of in vivo imaging systems consisting of bioluminescence, fluorescence, X-ray capable IVISes and a high-resolution MRI
PCM is excited to start using an online system to streamline the process of ordering and billing for core service requests. All facility users are invited to use the system, which requires a one-time registration, for more information go to https://www.yalecancercenter.org/research/resources/ilab/ Once you are registered, the system will enable you to request consultations, schedule equipment time, provide required approvals, and monitor progress.
Vish Muthusamy, PhD, Executive Director
(203) 785 3464
Marcus Bosenberg, MD, PhD, Scientific Director
(203) 737 3484